Abstract
BackgroundAlthough biologics have revolutionized treatment of juvenile idiopathic arthritis (JIA), many patients have active disease despite therapy [1]. Studies have shown benefit of dose intensification of infliximab in several conditions,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
